Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Sickle Cell Disease

What is sickle cell disease? Symptoms and treatments

Everything you need to know about sickle cell disease

Evening Standard

NHS calls for more black blood donors to help treat sickle cell disease

Demand for blood donations to treat the disease has risen by 67 per cent over the past five years

Evening Standard

What is sickle cell disease? Common symptoms and can it be treated?

Sickle cell disease is a serious and lifelong health condition. Here's everything you need to know about symptoms, causes and what treatment is available for it

Daily Mirror

From analysis to the latest developments in health,
read the most diverse news in one place.

Sickle cell disease: black donors urged to give blood as demand from patients soars

NHS says sickle cell is ‘fastest growing genetic condition in UK’ and demand for blood has jumped 67% in five years

The Guardian - UK

Record number of Black blood donors needed to treat sickle cell disease, NHS says

‘More demand for care than ever before,’ health chiefs say

The Independent UK

NHS makes ‘urgent’ call for black blood donors

More donors are needed to treat patients with sickle cell disease.

The Independent UK

Sickle cell: NHS to investigate racial inequalities for first time

Exclusive: Health chiefs hope findings will help to eradicate ‘often unacceptable, substandard’ care

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Too few kids with sickle cell disease get stroke screening, treatment, CDC finds

Fewer than half of children in the United States with sickle cell disease get a needed screening for stroke, and only about half or fewer get a treatment that can help with pain and anemia.

Chicago Sun-Times

Study: Too few kids with sickle cell get stroke screen, care

A study of U.S. children with sickle cell disease found fewer than half get a needed screening for stroke, a common complication

The Independent UK

Sickle cell disease — how one Black family is coping with the illness and inspiring others along the way

September is National Sickle Cell Awareness Month. The blood disorder occurs among about one of every 365 Black births and one of every 16,300 Latino births, according to the U.S. Centers for Disease Control and Prevention.

Chicago Sun-Times

What is sickle cell disease? Early symptoms from shortness of breath to tiredness

Sickle cell disease affects approximately 15,000 people in the UK. But what is it and what are the early signs to spot in children?

Daily Mirror

Silence, stigma and unaffordable drugs: the Kenyan woman finding sickle cell solutions

As a child, Lea Kilenga was ostracised because of her sickle cell disease. Now she is a champion for others

The Guardian - UK

Sickle cell disease: nearly 50% of patients receive poor care, says global study

Across 10 countries almost half those surveyed say they were treated like drug addicts and more than third believe their race influenced poor care

The Guardian - UK

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug Application (NDA) for elacestrant for patients with ER+/HER2- advanced or metastatic breast cancer. The agency has granted Priority Review designation and assigned a target action date of February 17, 2023. Radius Health…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

AFP

Pfizer to acquire sickle cell drugmaker GBT for $5 bn

New York (AFP) - American drugmaker Pfizer announced a deal on Monday to acquire Global Blood Therapeutics, makers of a recently approved treatment for sickle cell disease, for $5.4 billion.

Investors Business Daily

Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion

Rumors that Pfizer is in "advanced talks" to acquire Global Blood Therapeutics for about $5 billion sent GBT stock flying Friday.

Benzinga

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

The Conversation

There's no cure for sickle cell disease, but spotting it early can improve treatment

Most of the global cases of sickle cell disease are diagnosed in African countries. The Economist Intelligence Unit – the research and analysis division of the Economist media group – estimated that in 2020 the total annual cost of treatment and impact on the economy of sickle cell disease across…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Why Precision BioSciences Shares Are Surging Today

Precision BioSciences Inc (NASDAQ:DTIL) has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis AG (NYSE:NVS) Precision will develop a custom ARCUS nuclease that will be designed to insert, in vivo, a therapeutic transgene at a "safe harbor" location in the genome as a potential one-time…

Benzinga

Read Why Forma Therapeutics' Current Price Level Is 'Attractive Entry Point'

During the European Hematology Association (EHA) conference, Forma Therapeutics Holdings Inc (NASDAQ:FMTX) presented updated results from the 12-week open-label extension (OLE) of etavopivat's Phase 1 trial in sickle cell disease. Treatment with etavopivat 400mg QD elicited a >1g/dL hemoglobin (Hb) increase in 73% of the 15 patients and an average maximal Hb increase of…

Investors Business Daily

Do Crispr And Vertex Have A 'Functional Cure' For Blood Diseases?

Crispr Therapeutics could have a "functional cure" for two inherited blood diseases, analysts said Monday, but CRSP stock plummeted.

Benzinga

FDA Sounds Positive On Bluebird's One Gene Therapy But Doubts Another

The FDA signaled in briefing documents released that it may approve Bluebird bio Inc's (NASDAQ:BLUE) beti-cel gene therapy to treat β-thalassemia for those who require regular blood transfusions. The Prescription Drug User Fee Act (PDUFA) goal dates for beti-cel and eli-cel are August 19 and September 16. Bluebird bio's blood disorder treatment demonstrates "clinically meaningful"…

Benzinga

Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data

RBC Capital Markets says it remains on the sidelines given commercial uptake for CRISPR Therapeutics' (NASDAQ: CRSP) sickle cell disease (SCD)/beta-thalassemia (BT) capped by preconditioning and has little conviction in BCMA/CD70 data within weeks. The analysts lowered its price target to $85 from $95 to reflect higher Opex, with a Sector Perform rating. As recently…

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.